Phio Pharmaceuticals Corp. Common Stock
$1.03
$0.01 (+0.98%)
$1.01Day Range$1.06
Key Statistics
Market Cap
$11.97M
Shares Outstanding
11.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 10, 2012
Round Lot
100
Locale
US
Trading Data
Day Open
$1.04
Day High
$1.06
Day Low
$1.01
Volume
156.9K
VWAP
$1.04
Prev Close
$1.02
Transactions
--
Acc. Volume
--
About Phio Pharmaceuticals Corp. Common Stock
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
PHARMACEUTICAL PREPARATIONSSIC 28346 employees411 SWEDELAND ROAD, KING OF PRUSSIA, PA, 19406(508) 767-3861IPO May 10, 2012US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001533040
- Composite FIGI
- BBG0024FKD97
- Share Class FIGI
- BBG0024FKDB4
- Ticker Root
- PHIO
- SIC Code
- 2834
About Phio Pharmaceuticals Corp. Common Stock (PHIO) Stock
Phio Pharmaceuticals Corp. Common Stock (PHIO) closed the 2026-09-18 session at $1.03, up 0.98% versus the previous close (+0.01). The stock opened at $1.04 and traded between $1.01 and $1.06 during that session. Session trading volume was 157K shares. The volume-weighted average price (VWAP) is $1.04.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Phio Pharmaceuticals Corp. Common Stock has a market capitalization of $12.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. PHIO is listed on the XNAS exchange. The company employs approximately 6 people. Phio Pharmaceuticals Corp. Common Stock is headquartered in KING OF PRUSSIA, PA. The recorded listing date is 2012-05-10.
On this page you can find market PHIO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.